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Abstract
The matrix metalloproteinase family in humans comprises 23 enzymes, which are involved in
many biological processes and diseases. It was previously thought that these enzymes acted only
to degrade components of the extracellular matrix, but this view has changed with the discovery
that non-extracellular-matrix molecules are also substrates.
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Four decades ago a collagenase was discovered that was
responsible for involution of the tadpole tail in amphibian
morphogenesis [1]. Today, the matrix metalloproteinase
(MMP) family, to which this collagenase belongs, has
expanded to include 23 gene products in humans (Table 1),
which encode zinc-dependent and calcium-dependent pro-
teases that cleave within a polypeptide (endopeptidases).
There are also two other large families that have major roles
in extracellular proteolysis, the ADAM family (A disintegrin
and metalloprotease domain, with about 33 members in
humans) and the ADAMTS family (A disintegrin-like and
metalloprotease domain (reprolysin type) with throm-
bospondin type I repeats, with 19 members). Traditionally,
the MMPs have always been thought to cleave components
of the extracellular matrix (ECM). As the ECM was regarded
for a long time as nothing more than a passive structure
used for cell attachment, mechanical support and force
transmission, extracellular proteases such as MMPs were
thought to simply remodel the ECM for its homeostasis or
to facilitate cell migration. This view has changed, however
[2]: the ECM is now known to contain growth factors, their
binding proteins, and other bioactive molecules, as well as
binding sites for cell-surface molecules, some of which are
revealed only after proteolysis. The proteases responsible
for turnover of the ECM therefore contribute significantly
to its dynamic interactions with cells. More recently, con-
siderable evidence has emerged showing that the role of
MMPs goes far beyond that of digesting ECM molecules
alone; they are now known to process a number of cell-
surface and soluble regulators of cell behavior (summarized
in Table 1). Mouse genetic models and human diseases have
revealed unexpected biological functions of MMPs (summa-
rized in Table 2); many of the phenotypes of these animals
are currently unexplained and suggest that there may be as
yet unknown substrates for these enzymes that are not
ECM components.
One consequence of the previously held view of MMPs as
solely ECM-excavating enzymes was the belief that they were
uniformly harmful in cancer and should therefore be tar-
geted in cancer therapy. This was not entirely without basis,
given that many MMPs are highly expressed in various
cancers, both by tumor cells and in surrounding stromal
cells such as macrophages. As recent reviews [3-6] have
pointed out, however, the unexpectedly complex role of
these enzymes in cancer is leading to their re-evaluation as
drug targets, or at the very least, a pause while some of the
evidence is analyzed in more detail. Although this is disap-
pointing from the clinical perspective, the study of these
enzymes has never been more exciting than it is today,
because the human genome project has led to identification
of all MMPs, and genetic alterations in individual MMP
genes have provided new insights into their functions. In
this article, we summarize some of the essential concepts in
the MMP field at present and the new insights that are
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Table 1
Human matrix metalloproteases and their substrates
Protein name* Alternative names Collagenous substrates Non-collagenous ECM substrates Non-structural ECM component substrates
MMP-1 Collagenase-1 Collagen types I, II, III,   Aggrecan, casein, nidogen, serpins,  1-antichymotrypsin, 1-antitrypsin/
VII, VIII, X, and gelatin versican, perlecan, proteoglycan link  1-proteinase inhibitor, IGFBP-3, IGFBP-5, 
protein, and tenascin-C IL-1, L-selectin, ovostatin, recombinant
TNF- peptide, and SDF-1
MMP-2 Gelatinase-A Collagen types I, IV, V,  Aggrecan, elastin, fibronectin, laminin,  Active MMP-9, active MMP-13, FGF R1, 
VII, X, XI, XIV, and gelatin nidogen, proteoglycan link protein,  IGF-BP3, IGF-BP5, IL-1, recombinant 
and versican  TNF- peptide, and TGF-
MMP-3 Stromelysin-1 Collagen types II, IV, IX,  Aggrecan, casein, decorin,elastin,  1-antichymotrypsin, 1-proteinase
X, and gelatin fibronectin, laminin, nidogen,   inhibitor, antithrombin III, E-cadherin, 
perlecan, proteoglycan, proteoglycan  fibrinogen, IGF-BP3, L-selectin, ovostatin, 
link protein, and versican pro-HB-EGF, pro-IL-, pro-MMP-1, pro-
MMP8, pro-MMP-9, pro-TNF, and SDF-1
MMP-7 Matrilysin-1,  Collagen types I, II, III, V,  Aggrecan, casein, elastin, enactin,   4 integrin, decorin, defensin, E-cadherin, 
neutophil  IV, and X laminin, and proteoglycan link  Fas-L, plasminogen, pro-MMP-2, pro-MMP-7, 
collagenase protein pro-TNF, transferrin, and syndecan
MMP-8 Collagenase-2 Collagen types I, II, III, V,  Aggrecan, laminin, and nidogen 2-antiplasmin and pro-MMP-8
VII, VIII, X, and gelatin
MMP-9 Gelatinase-B Collagen types IV, V, VII,  Fibronectin, laminin, nidogen,  CXCL5, IL-1,  IL2-R, plasminogen, 
X, and XIV proteoglycan link protein, and   pro-TNF,  SDF-1, and TGF-
versican
MMP-10 Stromelysin-2 Collagen types III, IV, V,  Fibronectin, laminin, and nidogen Pro-MMP-1, pro-MMP-8, and pro-MMP-10
and gelatin
MMP-11 Stromelysin-3 Laminin 1-antitrypsin, 1-proteinase inhibitor, 
and IGFBP-1
MMP-12 Macrophage Elastin Plasminogen
metalloelastase
MMP-13 Collagenase-3 Collagen types I, II, III, IV,  Aggrecan, fibronectin, laminin,  Plasminogen activator 2, pro-MMP-9, 
V, IX, X, XI, and gelatin perlecan, and tenascin pro-MMP-13, and SDF-1
MMP-14 MT1-MMP Collagen types I, II, III,  Aggrecan, dermatan sulphate  v3 integrin, CD44, gC1qR, pro-MMP2, 
and gelatin proteoglycan, fibrin, fibronectin,  pro-MMP-13, pro-TNF, SDF-1, and tissue 
laminin, nidogen, perlecan, tenascin,  transglutaminase 
and vitronectin
MMP-15 MT2-MMP Collagen types I, II, III,  Aggrecan, fibronectin, laminin, nidogen,  Pro-MMP-2, pro-MMP-13, and tissue 
and gelatin perlecan, tenascin, and vitronectin  transglutaminase
MMP-16 MT3-MMP Collagen types I, III,  Aggrecan, casein, fibronectin, laminin,  Pro-MMP-2 and pro-MMP-13
and gelatin perlecan, and vitronectin
MMP-17 MT4-MMP Gelatin Fibrin and fibronectin
MMP-19 RASI-1 Collagens types I, IV,  Aggrecan, casein, fibronectin, laminin, 
and gelatin nidogen, and tenascin
MMP-20 Enamelysin Aggrecan, amelogenin, and cartilage 
oligomeric protein
MMP-21 1-antitrypsin
MMP-23 CA-MMP Gelatin
MMP-24 MT5-MMP Gelatin Chondroitin sulfate, dermatin sulfate,  Pro-MMP2 and pro-MMP-13
and fibronectin
MMP-25 Leukolysin, MT6-MMP Collagen type IV and gelatin Fibrin and fibronectin  Pro-MMP-2
MMP-26 Matrilysin-2, Collagen type IV  Casein, fibrinogen, and fibronectin 1-proteinase inhibitor
endometase and gelatin
MMP-28 Epilysin Casein
*Although there are 23 human MMPs, 29 numbers have been used in the literature. The symbols MMP-4, MMP-5, MMP-6 and MMP-29 are redundant in
humans and are no longer in use; MMP-18 corresponds to a Xenopus laevis collagenase, for which no human ortholog is known, and a human protein
published as MMP-18 is now called MMP-19. Two nearly identical human genes found in a segment of chromosome 1 that is duplicated were called
MMP21 and MMP22 but are now referred to as MMP23A and MMP23B. Classification and evolution
There are 23 human MMP genes (Table 1). Before this
genetic diversity was known, it was customary to divide the
MMPs into collagenases, gelatinases, stromelysins, elastase
and others, on the basis of the known substrates, but as
some MMPs have overlapping substrate specificities, the
boundary between the previously used enzyme classes is
now blurred. Nevertheless, the trivial names are often
useful, particularly if they reflect a function or a distinct
structural feature or location, and they have therefore been
retained (and are indicated in Table 1). MMP genes are
structurally similar to each other, indicating that they
evolved by duplication of a common ancestral gene followed
by divergent evolution. A number of MMP genes (MMP1,
MMP3, MMP7, MMP8, MMP10, MMP12, MMP13, MMP20,
and MMP26) are found in a cluster on human chromosome
11 (11q21-23) [7,8]. The human and mouse genomes appear
not to contain an identical complement of MMPs, which may
complicate the use of transgenic mice for insights into func-
tions of the human genes. For example, human MMP1 does
not have a clear-cut ortholog in the mouse but instead is
most similar to two genes, mColA and mColB, whose func-
tions are at present unknown [9]. 
MMP genes have been identified in a number of non-verte-
brate species, and the number will undoubtedly increase as
more genome projects are completed. The nematode
Caenorhabditis elegans has a number of MMPs, including
C31, H19 and Y19 [10]; there is a Drosophila MMP [11]; sea
urchins contain an MMP essential for hatching, known as
envelysin [12]; and the hydra has an MMP that is required
for foot-process development [13]. Interestingly, there is an
MMP in green algae [14] as well as in plants such as the
soybean [15] and Arabidopsis thaliana [16]. 
Domain organization and protein structure
The close evolutionary relationship between MMPs is further
reflected in the conservation of their domain structure
(Figure 1) and of their mechanisms of catalysis and regula-
tion. Most MMPs are secreted, although some are anchored
to the cell surface by a transmembrane segment (MMP-14,
MMP-15, MMP-16 and MMP-24, referred to as membrane-
type MMPs or MT-MMPs) [17] or via a glycosylphosphoinosi-
tol (GPI) anchor (MMP-17 and MMP-25, sometimes also
included in the MT-MMPs) [18]. Most of the MT-MMPs are
type I transmembrane proteins - oriented with the amino ter-
minus outside the cell - although one, MMP-23, is unusual in
apparently having the amino terminus positioned intracellu-
larly (a type II orientation) [19]. The MT-MMPs have a single
transmembrane domain followed by a short, highly con-
served cytosolic segment of 20 amino acids. ‘Soluble’ MMPs
may also be located at the cell surface via interaction with
membrane-bound molecules or complexes such as integrin
v3 [20], the extracellular matrix metalloproteinase inducer
EMMPRIN/CD147 [21], the hyaluronan receptor CD44 [22],
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Table 2
Phenotypes of knockout mice lacking MMP genes
Genotype Phenotype
MMP2-/- Suppression of experimentally induced pancreatic carcinogenesis [85]; suppression of angiogenesis and tumor growth [86]; delayed 
mammary gland differentiation; mild growth retardation.
MMP3-/- Accelerated mammary gland adipogenesis [87]; delayed incisional wound healing [88]; resistance to contact dermatitis [89]; impaired ex 
vivo herniated disc resorption [90].
MMP7-/- Suppression of experimental adenoma growth [91]; defective innate intestinal immunity [70]; impaired tracheal wound re-epithelization 
[92]; defective prostate involution after castration [93]; impaired ex vivo herniated disc resorption [94]; impaired transepithelial migration 
of neutrophils [32]; reduced syndecan-1 shedding [32].
MMP9-/- Suppression of experimentally induced skin carcinogenesis [95]; suppression of experimentally induced pancreatic carcinogenesis [85]; 
decreased experimental metastasis [86]; delayed growth plate vascularization [96]; abnormal endochondral ossification [96]; defective in 
osteoclast recruitment [97]; resistance to bullous pemphigoid (skin blistering) [98]; resistance to experimentally induced aortic aneurysms 
[99]; prolonged contact dermatitis [89]; protection from ventricular enlargement after infarction [100]; protection from cardiac rupture 
after infarction [101]; diminished peripheral mononucleocyte infiltrate in glomerular nephritis [102]; impaired smooth muscle cell migration
and geometrical arterial remodeling [103,104]; impaired cellular infiltration and bronchial hyper-responsiveness during allergen-induced 
airway inflammation [105]; impaired recruitment of stem and progenitor cells from the bone marrow following irradiation [106]; 
myocardial protection from ischemia and/or reperfusion [107].
MMP11-/- Suppression of experimentally induced mammary carcinogenesis [108]; decreased tumor cell survival and growth [109]; accelerated 
neointima formation after vessel injury [110].
MMP12-/- Resistance to cigarette-smoke-induced emphysema [111].
MMP14-/- Severe abnormalities in bone and connective tissue [76,77]; reduced collagen turnover [76]; impaired endochondral ossification [76,77]; 
defective angiogenesis [76,77].
Data in the table are modified from [5,77,83,112].domain - most commonly a domain similar to sequences in
the heme-binding protein hemopexin and the soluble
fibronectin-related protein vitronectin [24,25] (see Figure 1).
The protease domain contains a signal peptide, the pro-
domain, and the catalytic module, in that order. MMP-2 and
MMP-9, which are the main gelatinases, differ from other
MMPs in that they have three tandem fibronectin type II
cell-surface heparan-sulfate proteoglycans such as syndecans
[23], or transmembrane MMPs [17]. 
All MMPs except MMP-7 (matrilysin-1) and MMP-26
(endometase or matrilysin-2) consist of two domains con-
nected by a flexible proline-rich hinge peptide. The domains
comprise a protease domain and an ancillary (helper)
Figure 1
The domain composition and important structural features of the various subtypes of MMPs.
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Signal peptide
Pro-domain
Catalytic domain Furin cleavage site
Fibronectin type II repeats
Hinge region
Type V collagen-like domain
Carboxy-terminal transmembrane domain
GPI anchoring domain
Amino-terminal signal anchor
Cysteine array
Immunoglobulin-like domain
Cytoplasmic domain Hemopexin/vitronectin-
like domain
(b) Standard domain MMP-1, MMP-8, MMP-13, MMP-18,
MMP-10, MMP-12, MMP-19, 
MMP-20 and MMP-21
(d) Furin-activated MMP-11 and MMP-28
(a) Minimal domain MMP-7 and MMP-26
(c) Gelatin-binding MMP-2
(e) Transmembrane 
        (Type I)
MMP-14, MMP-15, MMP-16 
and MMP-24
(f) GPI-anchored MMP-17 and MMP-25
MMP-9
(g) Transmembrane 
        (Type II)     
MMP-23
Gelatin-bindingrepeats within the amino terminus of the catalytic module
that mediate gelatin binding (Figure 1c) [26-28]. MMP-9 has
an additional insert within its hinge region similar to colla-
gen V; its function is unknown. MMP-7 and MMP-26 [29]
lack the hemopexin/vitronectin-like domain (Figure 1a),
whereas MMP-23 has a unique cysteine- and proline-rich
sequence and a domain similar to the immunoglobulin-like
domains of the interleukin-1 receptor instead of the hemo-
pexin/vitronectin-like domain (Figure 1g) [30]. 
X-ray crystal structures are now available for a number of
MMPs, including full-length activated enzymes and zymogen
forms that include the pro-domain [31]. Crystallography has
revealed how a cleft in the active site contributes to enzyme
specificity [32]. The catalytic domain of all MMPs has a
unique signature of amino-acid residues (His-Glu-X-Gly-
His-X-X-Gly-X-X-His-Ser, where X is any amino acid)
within the active site [25] that coordinates the catalytic zinc
atom. The hemopexin/vitronectin-like domain consists of
four parts arranged symmetrically around a central axis,
forming a four-bladed propeller-like structure that helps to
confer substrate-binding specificity on the enzyme.
Regulation of MMPs
In keeping with their potential for tissue destruction, MMPs
are stringently regulated at multiple levels, including tran-
scription, activation of the zymogen forms, extracellular
inhibitors, location inside or outside the cell and internaliza-
tion by endocytosis. The pro-domain keeps the enzyme
latent using the thiol group of a highly conserved, unpaired
cysteine at its carboxyl terminus. This conserved cysteine
acts as a fourth inactivating ligand for the catalytic zinc atom
in the active site, resulting in the exclusion of water and ren-
dering the enzyme inactive (Figure 2). For the enzyme to be
activated, this cysteine-zinc pairing needs to be disrupted by
a conformational change or by proteolysis (such as by the
protease plasmin or by other MMPs). Once the thiol group is
replaced by water, the enzyme is able to hydrolyze the
propeptide to complete the activation process and can then
cleave the peptide bonds of its substrates. This system of
regulation is referred to as the ‘cysteine-switch’ mechanism
[33]. Most MMPs are not activated until they are outside the
cell, but the MT-MMPs and MMP-11, MMP-23 and MMP-28
are activated by a proprotein convertase (such as furin)
within the secretory pathway [34-37]. 
Once activated, there are multiple mechanisms that can
inactivate the MMPs [38]. Four classes of metalloproteinase
inhibitors are found in extracellular spaces and body fluids
that have broad inhibitory activity against many MMPs. One
class is the tissue inhibitors of metalloproteinases (TIMPs),
which are disulfide-bonded proteins of 20-30 kDa that
directly interact with the MMP active site through a small
number of their amino acids. An unrelated small inhibitor
derived by proteolysis of the procollagen C-proteinase
enhancer has structural similarity to TIMPs and may inhibit
MMPs through a similar mechanism [39]. Recently, a mem-
brane-anchored molecule, reversion-inducing cysteine-rich
protein with Kazal motifs (RECK), has been discovered that
appears to regulate MMP-2, MMP-9 and MMP-14 post-tran-
scriptionally by affecting secretion and activation as well as
by inhibition of the active site [40]. In the circulation, the
protease inhibitor 2-macroglobulin inactivates active
MMPs by a ‘bait and trap’ mechanism [38,41]: when pro-
tease-sensitive sites within the inhibitor are cleaved, it
springs closed around the proteinase and isolates it from
potential substrates. 
MMP zymogens can also be activated by MMPs themselves;
for example, MMP-2 is activated by MT-MMPs such as
MMP-14 [17]. Paradoxically, the inhibitor TIMP-2 is
absolutely required for this process, which requires it to bind
to the active site of MMP-14 and also, through its carboxy-
terminal domain, to the hemopexin/vitronectin-like domain
of MMP-2. The essential role of TIMP-2 is emphasized by
the lack of pro-MMP-2 activation in Timp2-null mice [42] as
well as by the exquisite co-regulation of the Mmp14 and
Timp2 genes (but not other TIMP genes) during mouse
development [43]. (MMP-14 also activates MMP-13 at the
cell surface, but this does not seem to require TIMP-2 [44].)
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Figure 2
The ‘cysteine-switch’ mechanism regulating the MMP zymogen. The thiol
group of a conserved cysteine (C) at the carboxyl terminus of the pro-
domain acts as a fourth inactivating ligand for the catalytic zinc atom in
the active site; this results in the exclusion of water and keeps the
enzyme latent. Displacement of the pro-domain by conformational change
or proteolysis disrupts this cysteine-zinc pairing and the thiol group is
replaced by water. The enzyme can then cleave the peptide bonds of its
substrates. 
H
H
H
Zn
Catalytic
domain
Pro-domain
Inactive 
enzyme
Water molecules
Active 
enzyme
Chemical or proteolytic
displacement of the 
pro-domain
C
H
H
H
ZnThe further activation of MMP-2 bound to TIMP2 probably
involves complex but highly regulated repositioning of mem-
brane-bound MMPs through their cytoplasmic tails or trans-
membrane domains or through interaction with cellular
receptors. Lehti et al. [45,46] have suggested that oligomer-
ization may occur between the cytoplasmic domains of the
two MMP-14 molecules, an observation that ties in with a
report that a conserved cysteine in the MMP-14 cytoplasmic
tail is essential for dimerization [47].
In addition to a possible role in oligomerization, the cytoplas-
mic domain of MT-MMPs is essential for regulating the activ-
ity of these enzymes; it acts by altering their spatial
distribution in the cell in response to intracellular signaling
events. The cytoplasmic sequence targets the MT-MMPs to
specific domains within the cell membrane, including
invadopodia (surface protrusions of invasive cells) [48] and
caveolae (specialized membrane invaginations) [49].
Recently, a role for the cytoplasmic domain has been identi-
fied in the cycling of MT-MMPs between an intracellular pool
and the cell surface via clathrin-coated pits and vesicles
[50,51]; this may be one of several cellular mechanisms by
which the amount of enzyme at the cell surface is regulated.
Studies of thrombospondin-2 null mice have indicated that
thrombospondin-2 has a role in targeting active MMP-2 to
the scavenger-receptor pathway [52], and it has been shown
that MMP-13 binds to a specific cell-surface receptor before it
is internalized via the low-density lipoprotein receptor [53].
Functions of MMPs
The substrates of MMPs are given in Table 1, and the func-
tions of MT-MMPs in particular are illustrated in Figure 3. 
Enzyme-substrate co-localization and interactions
The collagenases MMP-1, MMP-8, MMP-13, and MMP-14 are
the only MMPs that can efficiently degrade the fibrillar colla-
gens (types I, II and III) in their triple-helical domains [54].
Cleavage by these enzymes renders the collagen molecules
thermally unstable, so that they unwind to form gelatin,
after which they can be degraded by other members of the
MMP family such as the major gelatinases MMP-2 and
MMP-9. The collagenase active site is unable to accommo-
date the entire cross-section of the collagen triple helix, an
observation that has generated much interest in how this
substrate is actually cleaved. 
The two major gelatinases, MMP-2 and MMP-9, have
several distinctive features. They can be distinguished by the
fact that MMP-2 binds preferentially to TIMP-2, which is
required for its activation, whereas MMP-9 is preferentially
inhibited by TIMP-1 [38]. MMP-2 becomes located at the
cell surface by binding of its carboxyl terminus to the inte-
grin  v3 [29] or the MMP-14-TIMP-2 complex; when
bound, the catalytic site of MMP-2 is exposed and can be
cleaved and activated. The 2 chains of collagen IV bind
MMP-9 with a high affinity even when MMP-9 is inactive
[55]; this juxtaposition of enzyme and substrate means that
a pool of the enzyme is rapidly available upon activation for
any remodeling events. 
Non-matrix substrates and consequences of MMP
activity
The extracellular matrix contains sites that can bind growth
factors, either directly and via growth-factor-binding pro-
teins. When bound, growth factors - such as transforming
growth factor  (TGF-), fibroblast growth factor 1 (FGF-1)
and insulin-like growth factor 1 (IGF-1), tumor necrosis
factor , and heparin-binding epidermal growth factor-like
growth factor (HB-EGF) [56] - are unable to bind their recep-
tors and signal to the nucleus [57-61]. Several MMPs are able
to release growth factors by cleaving either the growth-factor-
binding protein or the matrix molecule to which these pro-
teins attach. In addition, MMP-3 and MMP-7 can cleave the
adherens-junction protein E-cadherin, thus promoting cell
invasion by disrupting cell aggregation [62,63]. MMP-3 can
release a soluble form of the adhesion molecule L-selectin
[64] from leukocytes. It also sheds membrane-bound
HB-EGF, so that it can exert signaling functions [56]. MMP-7
releases soluble Fas ligand; this occurs during involution of
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Figure 3
The locations of MT-MMPs. (a) The location of MT-MMPs lends them
critical biological roles at the cell surface: they cleave components of the
ECM, other MMPs and receptors for growth factors (which leads to
shedding of the receptors from the cells). (b) Mobilization of MT-MMPs
to the leading edge of cancer cells, where they remodel the ECM,
facilitates cell migration and tumor invasion.
ECM
proteolysis
Cell-surface
shedding
Pro-MMP
activation
MT-MMP
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the prostate after castration and induces apoptosis [65]. In
contrast to the activation of growth factors by proteolytic
release, many growth factors are proteolytically inactivated
by MMPs, including the chemokine connective tissue activat-
ing peptide III (CTAP-III), monocyte chemoattractant
protein and stromal cell-derived factor 1 (SDF-1) [66,67]. A
second mechanism by which growth factors and cytokines are
negatively regulated is when MPPs cause the shedding of
their receptors from the cell membranes, as in the case of
surface FGF receptor 1 [68].
The immune system is also influenced by MMPs. Firstly, the
defensins are a family of polar antimicrobial peptides that
make up part of the innate immune system of some animals.
Defensins are synthesized in an inactive form and activated by
the proteolytic removal of the pro-domain by MMP-7, which
allows them to insert into the bacterial membrane and disrupt
its integrity [69,70]. Secondly, MMP-3 (stromelysin-1) and
MMP-7 (matrilysin-1) can cleave all immunoglobulin G pro-
teins; this cleavage is important as it prevents the initiation of
the complement cascade and is potentially beneficial in the
removal of the immunoglobulin G from damaged or inflamed
tissue [71]. And finally, the receptor of the complement com-
ponent C1q, gC1qR, exists in both a membrane-bound form
and a soluble form that may inhibit the hemolytic activity of
C1q. By releasing gC1qR, MT1-MMP may help tumor cells to
avoid targeted destruction by the complement system and
may thus facilitate tumor-cell survival [72-74]. 
Genetic alterations in human and mouse MMPs
An extensive body of literature indicates an association of
MMPs with cancer, arthritis, numerous other inflammatory or
autoimmune disorders, cardiovascular and cerebrovascular
diseases, and fibrotic diseases. Despite this, there are rela-
tively few instances in which MMPs have proved to be the
primary cause of disease. One of these is a rare inherited dis-
order of bone (nodulosis arthropathy osteolysis syndrome),
one of a set of ‘vanishing bone syndromes’, in which there is
severe resorption and destruction of bones, primarily those of
the hands and feet [75]. The affected individuals also have
chronic arthritis and subcutaneous nodules in the hands and
feet. The disease is inherited in an autosomally recessive
manner, and loss-of-heterozygosity analysis mapped the
responsible gene to 16q12-q22, an interval containing the
MMP2 gene. Analysis of the serum and fibroblasts of affected
individuals showed a complete absence of MMP2. The family
was found to have two homoallelic MMP2 mutations, result-
ing in the ablation of MMP2 activity. The presence of collage-
nous nodules fits with the role of MMPs in removing excess
ECM; the paradox in these patients, however, is that excessive
destruction of bones and arthritis are caused by an absence of
a destructive enzyme, not an excess as might have been
expected. There are a number of mechanisms by which this
may occur: there may be compensatory overproduction of
another MMP or protease, MMP-2 may be essential for
processing of an inductive factor required for the activity of
bone-forming cells (osteoblasts), or it may be required to reg-
ulate the activity of bone-degrading cells (osteoclasts) in
tissues. Interestingly, the Mmp2  knockout mouse is not
known to recapitulate the human disease, which resembles
more closely the phenotype of Mmp14 knockout mice [76,77].
Given that MMP-14 and TIMP-2 are required for MMP-2 acti-
vation, it is possible that mutations in the genes encoding
these enzymes may result in a similar human disease.
The chromosome 1p36.3 region that contains the two closely
related MMP23 genes (see Table 1) is altered or frequently
deleted in neuroblastomas in which the oncogene MYCN has
been amplified, in a subset of malignant melanomas and in a
1p35 deletion disorder [78], but the role of the two MMP
genes in these disorders has not been investigated.
A polymorphism in the MMP1 promoter can result in one
allele having a sequence of either one or two guanines in a
particular position. The presence of two guanines results in
the de novo appearance of a binding site for the ETS-1 tran-
scription factor that cooperates with an adjacent site for the
AP-1 transcription factor to enhance the expression of MMP1
[79-81]. It is interesting to note that cancer patients, on
average, have a higher incidence of the two-guanine allele
than have people in the unaffected population. A regulatory
polymorphism is also present in the MMP3 promoter,
leading to the presence of either five or six adenosines [82].
The allele with six (6A) has a reduced transcriptional activity
compared to the allele with five. A study on patients with
coronary artery atherosclerosis revealed that patients
homozygous for the 6A allele showed a more rapid progres-
sion of both global and focal atherosclerotic lesions. 
The creation of transgenic mice that are null for specific
genes has been useful in attributing functions to a number of
MMP family members (Table 2). In general, most MMP gene
knockouts are viable, with subtle phenotypic differences from
their wild-type counterparts [83]. This could reflect either a
lack of function in vital developmental processes or a signifi-
cant amount of redundancy amongst these enzymes for sub-
strates, with the consequence that other family members can
be upregulated to compensate for the loss of an individual
enzyme. Although the lack of a dramatic phenotype in many
of the knockout mice may initially have seemed a disappoint-
ing outcome, it has in fact been very valuable for dissecting
the role of MMPs in cancer and inflammation. The exception
to the rule is the Mmp14-knockout mouse [76,77], which has
severe postnatal growth-retardation and skeletal anomalies
and dies before the onset of sexual maturity (Figure 4). The
severity of the Mmp14 knockout, in contrast to the other
MMP knockout animals, may reflect the position of this
enzyme as an initiator of a number of proteolytic cascades, as
well as its obligate location at the cell surface. (Note that none
of the other MT-MMPs has yet been inactivated in mice.) The
defects seen in these animals are probably attributable to
both deficiencies in the turnover of direct MMP-14 substratesand abnormalities in the indirect substrates that are medi-
ated by the activation of intermediary enzymes such as
MMP-2 and MMP-13. 
The importance of MMPs in physiological processes and
human disease is now undisputed. What is not known,
however, is the full extent to which they are involved in every
process in mammals. The failure of broad-spectrum and
even relatively specific MMP inhibitors in cancer therapy is
not surprising, because the complete effects for a given
inhibitor depend on the functions of its targets, and these
are mostly unidentified and unknown. The fact that there are
two other large families of related proteases with important
physiological functions, the ADAM and ADAMTS families,
suggests that additional caution should be taken when using
MMP inhibitors to treat disease states. More subtle
approaches are going to be required to modulate the func-
tions of these enzymes in a more selective fashion [84]. By
understanding the precise mechanisms by which MMPs are
regulated and their interactions with various binding part-
ners, it may be possible to block the deleterious functions of
these enzymes without the concomitant loss of beneficial
functions. This underscores the need for a greater investment
than ever before in MMP biology and biochemistry. The next
five years are expected to bring many exciting insights into
the role of MMPs in development and human disease and
may lead to even broader interest in what was once thought
to be a highly specialized and restricted field.
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